C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 120 filers reported holding C4 THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.07 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $225,367 | +49.6% | 121,165 | +121.2% | 0.00% | – |
| Q2 2023 | $150,610 | -56.5% | 54,767 | -50.3% | 0.00% | – |
| Q1 2023 | $346,040 | +12.1% | 110,204 | +110.6% | 0.00% | – |
| Q4 2022 | $308,800 | -38.7% | 52,339 | -9.0% | 0.00% | – |
| Q3 2022 | $504,000 | +4940.0% | 57,520 | +4290.8% | 0.00% | – |
| Q2 2022 | $10,000 | -99.9% | 1,310 | -99.8% | 0.00% | -100.0% |
| Q1 2022 | $14,539,000 | -30.4% | 599,281 | -7.7% | 0.00% | -50.0% |
| Q4 2021 | $20,897,000 | -27.9% | 648,981 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $28,996,000 | +32.3% | 648,981 | +12.0% | 0.00% | 0.0% |
| Q2 2021 | $21,920,000 | +75.1% | 579,281 | +71.2% | 0.00% | +100.0% |
| Q1 2021 | $12,517,000 | -43.7% | 338,387 | -49.6% | 0.00% | -50.0% |
| Q4 2020 | $22,240,000 | – | 671,287 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |